Signet Financial Management LLC Sells 73 Shares of Eli Lilly and Company $LLY

Signet Financial Management LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 0.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,629 shares of the company’s stock after selling 73 shares during the quarter. Eli Lilly and Company comprises 1.0% of Signet Financial Management LLC’s holdings, making the stock its 23rd largest holding. Signet Financial Management LLC’s holdings in Eli Lilly and Company were worth $8,285,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Hobbs Wealth Management LLC increased its stake in Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock valued at $1,205,000 after purchasing an additional 12 shares in the last quarter. Hixon Zuercher LLC increased its position in Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock valued at $1,477,000 after buying an additional 12 shares in the last quarter. O Brien Wealth Partners LLC increased its position in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after buying an additional 12 shares in the last quarter. Ascent Capital Management LLC increased its holdings in shares of Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after acquiring an additional 12 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners increased its holdings in shares of Eli Lilly and Company by 2.7% during the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company’s stock valued at $407,000 after acquiring an additional 13 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. HSBC upgraded shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and boosted their price target for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Guggenheim decreased their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Finally, Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $939.61.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $742.51 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $939.30. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a fifty day moving average price of $736.05 and a 200-day moving average price of $768.68. The firm has a market cap of $702.75 billion, a price-to-earnings ratio of 48.53, a PEG ratio of 1.04 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.